Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

References

• Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv259–iv259. doi:10.1093/annonc/mdy157.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Wahner Hendrickson AE, Jatoi A, Burton JK, Paroly J, Glaspy JA, Dowdy SC, Slamon DJ. A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. J Clin Oncol. 2016;34:5557. doi:10.1200/JCO.2016.34.15_suppl.5557.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer - Full Text View - ClinicalTrials.gov [Internet]. [accessed 2018 Dec 3]. https://clinicaltrials.gov/ct2/show/NCT02657928.
   Google Scholar
• Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936. doi:10.1056/NEJMoa1607303.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–1936. doi:10.1056/NEJMoa1810527.
   PubMed Web of Science ®Google Scholar
• US National library of Medicine – Genetic Home. Cyclin dependent kinase inhibitor 2A [Internet]. [accessed 2018 Dec 3]. https://ghr.nlm.nih.gov/gene/CDKN2A.
   Google Scholar
• Zhao R, Choi BY, Lee M-H, Bode AM, Dong Z. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer. EBioMedicine. 2016;8:30–39. doi:10.1016/j.ebiom.2016.04.017.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29:4018–4032. doi:10.1038/onc.2010.154.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang H-J, Anderson L, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011;17:1591–1602. doi:10.1158/1078-0432.CCR-10-2307.
   PubMed Web of Science ®Google Scholar
• Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, et al. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci. 2016;107:755–763. doi:10.1111/cas.2016.107.issue-6.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. Open Access PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
   Google Scholar
• Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2014;16:25–35. doi:10.1016/S1470-2045(14)71159-3.
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: phase II Activity, Safety, and Predictive Biomarker Assessment. Clin Cancer Res. 2015;21:995–1001. doi:10.1158/1078-0432.CCR-14-2258.
   PubMed Web of Science ®Google Scholar
• Finn R, Liu Y, Martin M, Rugo H, Dieras V, Im S-A, Gelmon K, Harbeck N, Zhu Z, Lu D, et al. Abstract P2-09-10: comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study. Cancer Res. 2018;78:09–10. P2-09-10-P2-.
   Web of Science ®Google Scholar
• Condorelli R, Spring L, O’Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29:640–645. doi:10.1093/annonc/mdx784.
   PubMed Web of Science ®Google Scholar
• Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Zhang Z, et al. Abstract CT039: cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial. Cancer Res. 2018;78:CT039–CT039.
   Web of Science ®Google Scholar
• Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol. 2019. JCO1800925. doi:10.1200/JCO.18.00925.
   Google Scholar
• Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Wong -K-K, Izaguirre DI, Kwan S-Y, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol. 2013;130:565–569. doi:10.1016/j.ygyno.2013.06.016.
   PubMed Web of Science ®Google Scholar
• Vang R, Levine DA, Soslow RA, Zaloudek C, Shih I-M, Kurman RJ. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. Int J Gynecol Pathol. 2016;35:48–55. doi:10.1097/PGP.0000000000000207.
   PubMed Web of Science ®Google Scholar
• Williams C, Simera I, Bryant A, Platt J. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010.17(3):CD001034.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. Hormone Receptors in Serous Ovarian Carcinoma: prognosis, Pathogenesis, and Treatment Considerations. Clin Med Insights Oncol. 2016;10:17–25. doi:10.4137/CMO.S32813.
   PubMed Web of Science ®Google Scholar
• Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, et al. Paragon (ANZGOG-0903): phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer. 2017;27:900–906. doi:10.1097/IGC.0000000000000978.
   PubMed Web of Science ®Google Scholar
• Lee NV, Yuan J, Eisele K, Cao JQ, Painter CL, Chionis J, Liu C, Shields DJ, Kan JLC, Arndt K, et al. Abstract LB-136: mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer. Cancer Res. 2014;74:LB-136-LB–136.
   Web of Science ®Google Scholar